Hashimoto H, Ogawa N, Hagihara N, Yamamoto K, Imanishi K, Nogi H, Nishino A, Fujita T, Matsuda T, Nagata S, Baba A
Department of Pharmacology, Faculty of Pharmaceutical Sciences, Osaka University, Suita, Japan.
Mol Pharmacol. 1997 Jul;52(1):128-35. doi: 10.1124/mol.52.1.128.
Vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) receptors are closely related G protein-coupled receptors with seven-transmembrane domains. The VIP receptor can bind both VIP and PACAP with high affinity, whereas the PACAP receptor binds only PACAP with high affinity. To elucidate the structural domains involved in a selectivity for VIP binding and the subsequent receptor activation, a series of chimeric receptors between the VIP and PACAP receptors was constructed, expressed in COS-7 cells, and analyzed for ligand binding and cAMP generation. All chimeric constructs bound PACAP with high affinity and subsequently activated cAMP generation similarly to the wild-type receptors. In contrast, profound differences were observed in the potencies of VIP for competition of 125I-labeled PACAP binding to both wild-type receptors and the chimeric receptors. The cAMP responses of these receptors generally correlated with the ability of VIP to compete for PACAP radioligand binding with the exceptions for some particular chimeras. In this report we demonstrate that several domains, including the amino-terminal extracellular domain, the transmembrane domains I and II, and the first extracellular loop of the VIP receptor, are important for the selectivity for VIP binding and responsiveness to VIP. We further show that the third extracellular loop and its proximal domains of the VIP receptor appear to be involved in the VIP recognition, especially the receptor activation process. On the other hand, the direct binding experiments of the VIP radioligand demonstrated that both wild-type receptors and all chimeric receptors have a high affinity binding site for VIP, although this high affinity VIP binding resulted in a biological response only in the VIP receptor or VIP receptor-like chimeras. This suggests that there is a nonbiologically relevant high affinity VIP-binding site within the rat PACAP receptor.
血管活性肠肽(VIP)受体和垂体腺苷酸环化酶激活肽(PACAP)受体是密切相关的G蛋白偶联受体,具有七个跨膜结构域。VIP受体能以高亲和力结合VIP和PACAP,而PACAP受体仅以高亲和力结合PACAP。为了阐明参与VIP结合选择性及随后受体激活的结构域,构建了一系列VIP受体和PACAP受体之间的嵌合受体,在COS-7细胞中表达,并分析其配体结合和cAMP生成情况。所有嵌合构建体都以高亲和力结合PACAP,随后激活cAMP生成,与野生型受体相似。相比之下,观察到VIP对125I标记的PACAP与野生型受体和嵌合受体结合竞争的效力存在显著差异。这些受体的cAMP反应通常与VIP竞争PACAP放射性配体结合的能力相关,但某些特定嵌合体除外。在本报告中,我们证明了几个结构域,包括氨基末端细胞外结构域、跨膜结构域I和II以及VIP受体的第一个细胞外环,对于VIP结合选择性和对VIP的反应性很重要。我们进一步表明,VIP受体第三个细胞外环及其近端结构域似乎参与VIP识别,尤其是受体激活过程。另一方面,VIP放射性配体的直接结合实验表明,野生型受体和所有嵌合受体都有一个VIP高亲和力结合位点,尽管这种高亲和力VIP结合仅在VIP受体或类VIP受体嵌合体中产生生物学反应。这表明大鼠PACAP受体中存在一个与生物学无关的VIP高亲和力结合位点。